INCR — InterCure Income Statement
0.000.00%
- $67.73m
- $94.36m
- ILS355.55m
- 60
- 80
- 69
- 80
Annual income statement for InterCure, fiscal year end - December 31st, ILS millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8.93 | 65 | 220 | 389 | 356 |
Cost of Revenue | |||||
Gross Profit | 1.47 | 30.4 | 96 | 159 | 108 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.3 | 103 | 191 | 338 | 397 |
Operating Profit | -3.42 | -38.4 | 28.2 | 50.6 | -41.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.57 | -38.3 | 18.7 | 43.8 | -61.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.89 | -36 | 7.3 | 43.7 | -63.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -5.89 | -37.2 | 4.69 | 44.8 | -62 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.89 | -37.2 | 4.69 | 44.8 | -62 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.253 | -1.46 | 0.167 | 1.07 | -0.348 |
Dividends per Share |